Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27233005 | 0.89 | GAA (0.54) | GAAALDH1A1KMT2ALMNAHTT | |
| SCHEMBL7875596 | 0.85 | GAA (0.51) | GAAALDH1A1KMT2ALMNAHTT | |
| SCHEMBL3071598 | 0.84 | GAA (0.80) | GAAALDH1A1RAB9AKMT2ALMNA | |
| SCHEMBL5940592 | 0.84 | RAB9A (0.74) | GAAALDH1A1ALOX12RAB9AKMT2A | |
| SCHEMBL10620309 | 0.83 | ALDH1A1 (0.50) | GAAALDH1A1KMT2ALMNAHTT | |
| SCHEMBL11527006 | 0.81 | GAA (0.53) | GAAALDH1A1KMT2ALMNAHTT | |
| SCHEMBL2908793 | 0.80 | HSD17B10 (0.78) | GAAALDH1A1ALOX12RAB9AKMT2A | |
| SCHEMBL6865356 | 0.79 | GAA (0.51) | GAAALDH1A1KMT2ALMNAHTT | |
| SCHEMBL3071601 | 0.78 | MEN1 (0.56) | GAAALDH1A1RAB9AKMT2ALMNA | |
| SCHEMBL9678195 | 0.78 | TSHR (0.53) | GAAALDH1A1RAB9AKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0755250-A4 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS INC (US) | 2000-04-19 | — | — | EP | claimed |
| EP-0755250-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-01-29 | — | — | EP | claimed |
| US-5472983-A | Neurodegenerative conditions associated with dopamine depletion, e.g. Alzheimer's, Parkinson's, multiple sclerosis, Huntington's amyltrophic lateral sclerosis and vision defects | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-12-05 | — | — | US | claimed |
| WO-1995028153-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | claimed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| EP-0755250-A4 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS INC (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0755250-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5472983-A | Neurodegenerative conditions associated with dopamine depletion, e.g. Alzheimer's, Parkinson's, multiple sclerosis, Huntington's amyltrophic lateral sclerosis and vision defects | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1995028153-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | GAA 949/4885ALDH1A1 3932/4885ALOX12 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.